Below, you will find a list of our latest press releases, and other newsworthy events.
|
|
|
|
|
|
|
|
|
|
|
|
12/8/2010
TYRX, Inc. Raises $20 Million in Private Financing
“This continued investment from Clarus and Pappas Ventures, along with participation from new TYRX investor HLM Venture Partners, is a strong validation of TYRX’s products and business strategy,” stated Robert White, TYRX’s Chief Executive Officer
|
|
|
|
|
|
|
|
4/21/2010
TYRX Names Randy Mansfield as Vice President of Marketing
"Randy brings a very broad background of commercialization and market development skills and experience,” remarked Robert S. White, President and Chief Executive Officer. “Randy’s history in leading Kyphon’s marketing efforts will be invaluable as we continue to accelerate the market expansion of our AIGISRx® product lines.”
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
4/20/2009
Surgical Site Infection Education
A special supplement to the May issue of EP Lab Digest, featuring articles by Daniel Z. Uslan, MD, Rabih O. Darouiche, MD and Matthew R. Reynolds, MD, MSc
|
|
|
|
11/25/2008
1,000th implant of the AIGISRx™ Anti-bacterial Envelope
TYRX, Inc., a leader in the development and commercialization of convergent drug-device products, announced today the 1,000th implant of the AIGISRx™ Anti-Bacterial Envelope following its commercialization in June, 2008. AIGISRx is an anti-bacterial surgical mesh developed to deliver anti-microbial agents that help provide protection against infections associated with implanted pacemakers and cardioverter defibrillators.
|
|
11/10/2008
TYRX Appoints William Dempsey, Independent Director
TYRX, Inc., a leader in the development and commercialization of combination drug-device technologies, today announced the appointment of William G. Dempsey as Independent Director, bringing the TYRX Board membership to seven.
|
|
5/14/2008
TYRX Pharma, Inc. Announces the First Human Implant of the AIGISRx™ Anti-Bacterial Envelope in Cardiac Patient
TYRX Pharma, Inc., the leader in the marketing of convergent drug-device products, announced today that the first commercial implant of the AIGISRx™ Anti-Bacterial Envelope in a CRMD procedure was conducted at St. Luke’s Episcopal Hospital of the Texas Heart Institute in Houston.
The new antibacterial envelope device is designed to stabilize pacemakers (IPG) and implantable cardioverter defibrillators (ICD) with the additional benefit of reducing potential risks of infections associated with implantation.
|
|
2/27/2008
TYRX Pharma, Inc. Raises $25 Million in Private Financing
TYRX Pharma, Inc., a leader in the commercialization of implantable combination drug - device products, announced today that the Company has raised $25 million in a venture capital financing led by Clarus Ventures and co-led by Pappas Ventures.
|
|
|
|
10/19/2007
TYRX Pharma, Inc. Announces Presentation of Results to Benefit Women with Breast Implants (In-Vivo Efficacy Study Regarding AIGISRx DEB)
TYRX Pharma, Inc., a leader in the commercialization of implantable medical-pharmaceutical devices, announced today acceptance for presentation during the Plastic Surgery 2007 Society meeting, (October 26-31, 2007, Baltimore, MD) the paper entitled, “Prevention of Experimental Capsular Contracture in Breast Implants by an Antimicrobial-Impregnated Biodegradable Wrap”. These study results demonstrate the potential of the TyRx AIGISRx DEB technology to address a significant unmet clinical need for women who have had breast augmentation.
|
|
|
|
|
|
|
|
1/29/2007
TYRX Pharma, Inc. Announces Strategic Alliance
TYRX Pharma, Inc., a privately held company located in Monmouth Junction, NJ, today announced that it has entered into a strategic alliance with C. R. Bard, Inc. (“Bard”) for certain TyRx technologies.
|
|
10/16/2006
TYRX Pharma, Inc. Announces Submission of a Premarket Application for PIVIT™ CRM
TYRX Pharma, Inc. announced today that it has filed a Premarket Application for PIVIT™ CRM, an innovative mesh pouch coated with a proprietary bioresorbable polymer containing the antimicrobial agents rifampin and minocycline designed to enclose a pacemaker or ICD pulse generator when implanted in the body. PIVIT™ CRM acts to provide protection from microbial colonization of the pulse generator during surgical implantation.
|
|
|
|
6/30/2006
TYRX Pharma, Inc., and Forrest T. Smith, PhD, Awarded the 2006 Fruchaud Prize for Best Scientific Poster Presentation during the 3rd International Hernia Congress
TYRX Pharma, Inc today announced that an independent panel of three judges on behalf of the International Hernia Congress awarded TyRx Pharma, Inc., and Forrest T. Smith, PhD, Associate Professor of Clinical Toxicology and Pharmacology, Virginia Commonwealth University (Richmond), the 2006 Fruchaud Prize for Best Scientific Poster Presentation during the 3rd International
Hernia Congress.
|
|
|
|
|
|
|
|
1/17/2006
TYRX Announces FDA 510(k) Filing for New Antibiotic Eluting Surgical Mesh
TYRX Pharma, Inc. announced today that it has recently filed a 510(k) application with the U.S. Food and Drug Administration (FDA) for its novel antimicrobial surgical mesh product. TyRx expects
to launch this new surgical mesh in Q1-06. This is the second in a series of combination medical products that TyRx expects to market next year. In December 2005, FDA granted 510(k) clearance for TyRx’s new bioresorbable polymer coated surgical mesh product. Like its predecessor, the TyRx antimicrobial mesh is designed to facilitate insertion and improve patient comfort long-term.
|
|
1/9/2006
TYRX Pharma’s Anesthetic Coated Surgical Mesh Combination Product Assigned to “Device” Center at FDA
TYRX Pharma, Inc., announced today that its Anesthetic Coated Surgical Mesh has received a designation of “Combination Product with Device Primary Mode of Action (PMOA)” from the Office of Combination Products at the U.S. Food and Drug Administration (FDA). This designation and assignment to the Center for Devices and Radiologic Health (CDRH) has historically indicated a faster regulatory and commercial timeline for a product as compared to when the FDA considers a combination product to be a “drug”.
|
|
1/3/2006
TYRX Announces FDA 510(k) Clearance for New Surgical Mesh
TYRX Pharma, Inc. announced today that the FDA granted 510(k) clearance for its new bioresorbable polymer coated surgical mesh product. TyRx expects to launch this new surgical mesh in Q1-06. This is the first in a series of devices and combination medical products that TyRx expects to market next year.
|
|
11/7/2005
TYRX Pharma, Inc. Joins the Combination Products Coalition
TYRX Pharma, Inc. today announced its membership with the Combination Products Coalition (CPC). TyRx joins a group of leading companies in the drug, device and biologics industries that will facilitate development of the regulatory environment for combination medical products by advocating policy positions on FDA regulatory issues affecting combination products. The CPC is coordinated through the office of Bradley Thompson of the Law firm of Baker and Daniels. TyRx will be represented at the CPC by Mason Diamond, Vice President for Clinical and Regulatory Affairs.
|
|
|
|
5/9/2005
TYRX Pharma, Inc. Announces Two Senior Staff Additions
TYRX Pharma, Inc., a privately held company located in Monmouth Junction, NJ, today announced two new additions to its management team: William C. McJames as Vice President of Product Development and Mason Diamond, D.D.S. as Vice President of Clinical and Regulatory Affairs.
|
|
1/31/2005
TYRX Pharma, Inc. Announces Equity Investment by Boston Scientific Corporation
TYRX Pharma, Inc., a privately held company located in Monmouth Junction, NJ, today announced that it has received an equity investment from Boston Scientific Corporation. Since 2002, Boston Scientific and TyRx have been co-developing novel drug eluting coatings for cardiovascular stents under a licensing agreement. TyRx is focused on developing a family of proprietary bioresorbable drug-eluting polymers for use in combination medical devices and specialty pharmaceuticals.
|
|